Immunomedics (Nasdaq: IMMU) has at last won approval for the first Trop-2 targeting antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy).
The option was given an accelerated approval for people with metastatic triple-negative breast cancer (mTNBC), in the third-line setting.
It hasn’t been a straight road to approval for the New Jersey, USA-based firm, with the US regulator earlier rejecting a bid for accelerated approval, on the basis of quality control problems, including a data integrity breach.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze